Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...

New York University researchers say a simple, gene-based blood test has shown to be highly accurate in predicting whether ...

At the same time, drugmakers have come to rely on the U.S. market for the bulk of their revenue. In 2022, the U.S. accounted ...

(Reuters) - Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the ...

The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

A three-judge panel wrestled Thursday with Novartis AG’s challenge against the FDA over its approval of a generic version of ...

Novartis has terminated a phase 2 trial evaluating an investigational ADAMTS-5 inhibitor for patients with osteoarthritis knee pain. The Big Pharma company discontinued the study testing intra ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

Swiss drugmaker Novartis is planning to spend $23 billion at 10 of its U.S. facilities — including one in Millburn — as the company and the pharmaceutical industry as a whole grapple with the ...

Nikki Odum was on vacation with her family when she noticed something unusual — a strange shape under her armpit near her left breast. At 36 years old, this discovery was both unexpected and alarming.